Aulos Bioscience

We’re revolutionizing #cancercare through #IL2 therapeutics designed to direct the #immunesystem to destroy cancers. #ImmunoOncology #Oncology

[Aulos Bioscience @AulosBioscience]

At #ASCO26, CEO Aron Knickerbocker joined @BiotechTV to discuss our new Phase 2 data for imneskibart in doublet checkpoint inhibitor-refractory metastatic melanoma, including a 33% objective response rate (ORR) and 67% disease control rate (DCR).

Aron walks through the positive results from the cohorts evaluating imneskibart and low-dose, subcutaneous aldesleukin with and without a checkpoint inhibitor (nivolumab), and outlines the next steps in our clinical development path.

#CancerResearch #Immunotherapy

[BiotechTV @BiotechTV]

𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟔: @AulosBioscience presented updated phase 2 data in checkpoint inhibitor-refractory metastatic melanoma for its IL-2 redirecting antibody, imneskibart. #ASCO26

Full video: https://t.co/6dCpG3OzhD

[Aulos Bioscience @AulosBioscience]

Beyond melanoma, imneskibart is advancing in non-small cell lung cancer. Two ongoing Phase 2 cohorts are evaluating imneskibart and low-dose, subcutaneous aldesleukin — with and without avelumab (anti-PD-L1 with an active Fc domain and ADCC effector function) — in patients with advanced PD-L1+ #NSCLC that progressed on prior CPI therapy. We anticipate sharing clinical data by year-end.

Learn more about our approach: https://t.co/N8IoUGjlGV

#CancerResearch #Immunotherapy #LungCancer

[Aulos Bioscience @AulosBioscience]

Our time at #ASCO26 reaffirmed why we do this work — alongside clinicians, scientists and partners committed to better outcomes for patients with cancer. At Aulos, our focus remains steady: building on the new Phase 2 data we shared for imneskibart in doublet checkpoint inhibitor-refractory metastatic melanoma, and continuing to advance this selective immune-activating therapy in additional checkpoint inhibitor-refractory tumors, including non-small cell lung cancer.

Thank you to the investigators, clinical teams and patients whose participation makes this progress possible.

#CancerResearch #Immunotherapy

[Aulos Bioscience @AulosBioscience]

New Phase 2 data at #ASCO26: 33% objective response rate and 67% disease control rate in doublet checkpoint inhibitor-refractory metastatic melanoma patients treated with the imneskibart triplet regimen. Read the data: https://t.co/btShH9EwT9

#ASCO26 #Immunotherapy #CancerResearch #IL2

[Aulos Bioscience @AulosBioscience]

At the @ASCO Annual Meeting, Aulos is presenting Phase 1/2 data for imneskibart in doublet checkpoint inhibitor-refractory cutaneous melanoma — a setting with limited options for patients following tumor progression on anti–PD-1/anti–CTLA-4 or anti–PD-1/anti–LAG-3 combinations. We’re excited to share our findings with the oncology community.

Learn more: https://t.co/u7eOQds6Ps
#ASCO2026 #Melanoma #ImmunoOncology #Biotech #medex

[Aulos Bioscience @AulosBioscience]

The imneskibart story extends beyond the tumor microenvironment. Selective IL-2 engagement is designed to maintain immune activation while limiting toxicities — including vascular leak syndrome and pulmonary edema — that have historically constrained this pathway.

Learn more: https://t.co/raGYdjlMqU
#CancerEducation #ImmunoOncology #MedEd

[Aulos Bioscience @AulosBioscience]

The #TumorMicroenvironment (TME) plays a powerful role in cancer progression and treatment response.

At Aulos, we're exploring innovative therapies to effectively modulate the TME, enhancing immune responses against tumors.

Learn more about our approach: https://t.co/raGYdjlMqU

#CancerEducation #ImmunoOncology

[Aulos Bioscience @AulosBioscience]

The 2025 #NobelPrize in Medicine honors the scientists who discovered immunosuppressive regulatory T cells (Tregs) — a breakthrough that reshaped immunology. Imneskibart builds on this legacy by activating Teffs & NK cells while limiting Tregs in solid tumor cancers.

#Immunotherapy #Tregs #CancerResearch

[Aulos Bioscience @AulosBioscience]

This Thanksgiving, we’re grateful for the patients, families, investigators and clinical teams who make progress in immuno-oncology possible. Your trust and commitment drive every step forward.

Thank you.

#Thanksgiving

[Aulos Bioscience @AulosBioscience]

Aulos is featured in @DDWJournal’s “One to Watch” spotlight.

CEO Aron Knickerbocker explains how imneskibart was designed to minimize the challenges of immune activation, while driving durable tumor reductions in #melanoma, #NSCLC and other tumor types.

Read more: https://t.co/hFtHjYWGdO

#CancerResearch #Immunotherapy

[Aulos Bioscience @AulosBioscience]

CEO Aron Knickerbocker spoke with BiotechTV at #SITC2025 about the latest Phase 2 imneskibart data — showing responses in #melanoma and #LungCancer, and higher Teff/Treg ratios that may correlate with longer time on treatment and overall survival for patients. 

Watch here: https://t.co/5E5Gfp5B1k

#CancerResearch #Immunotherapy

[Aulos Bioscience @AulosBioscience]

Grateful for the science and collaboration that defined #SITC2025. 

As we head into the final months of 2025, we’re moving forward with the same purpose: advancing imneskibart and the promise of this selective immune-activating therapy for patients. 

Learn more about Aulos: https://t.co/2rEKRfgacS

#CancerResearch #Immunotherapy

[Aulos Bioscience @AulosBioscience]

At #SITC2025, we’re spotlighting the convergence of science and technology driving selective IL-2 innovation. Imneskibart shows what’s possible when precision design meets real-world oncology needs.

Learn more: https://t.co/4eoXzaIBxu

#Cytokines #AIinHealthcare #Biotech

[Aulos Bioscience @AulosBioscience]

Ahead of #SITC2025: Explore how selective IL-2 biology can help the immune system do what it does best—fight cancer with precision.

Learn more about our work: https://t.co/80YGbRgeeI

#Immunotherapy #CancerResearch

[Aulos Bioscience @AulosBioscience]

Listen as CEO Aron Knickerbocker discusses the promising clinical progress of imneskibart and our focus on patient safety: https://t.co/YvmlI1GNUj

#CancerResearch

[Aulos Bioscience @AulosBioscience]

Cytokines are immune messengers that activate tumor-fighting cells. At Aulos, we're precisely directing IL-2 for stronger, targeted responses.

Learn more: https://t.co/80YGbRgeeI

#Immunotherapy #CancerResearch

[Aulos Bioscience @AulosBioscience]

#News: We’re sharing updated Phase 2 data for imneskibart (AU-007) in checkpoint inhibitor (CPI)-refractory #melanoma & #NSCLC at #SITC25.

Learn more: https://t.co/QTvYKfHD7K

#Immunotherapy #CancerResearch

[Aulos Bioscience @AulosBioscience]

Today we honor cancer research innovation. At Aulos, we’ve leveraged machine learning along with immunology expertise to advance a precise immunotherapy, imneskibart (AU-007).

#WorldCancerResearchDay #CancerResearch

[Aulos Bioscience @AulosBioscience]

Hear how AI played a key role in helping design imneskibart, our IL-2 antibody candidate, from CEO Aron Knickerbocker: https://t.co/YvmlI1GNUj
#AIinHealthcare

[Aulos Bioscience @AulosBioscience]

What have we learned about #IL2? It boosts immune cells to fight tumors—but also activates regulatory T cells (Tregs), which suppress immune responses. Effective IL-2 therapy requires precisely targeting the right cells and avoiding unwanted suppression.

Learn more: https://t.co/T1UG2aPiV0

#CancerScience #ImmunoOncology #MedEd